rs1230597000
Variant names:
Variant summary
Our verdict is Likely benign. The variant received -5 ACMG points: 2P and 7B. PM2BP4_StrongBP6_ModerateBP7
The NM_001330723.2(SNX27):c.1287T>C(p.Phe429Phe) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000141 in 1,421,876 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).
Frequency
Genomes: not found (cov: 30)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
SNX27
NM_001330723.2 synonymous
NM_001330723.2 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 2.06
Publications
0 publications found
Genes affected
SNX27 (HGNC:20073): (sorting nexin 27) This gene encodes a member of the sorting nexin family, a diverse group of cytoplasmic and membrane-associated proteins involved in endocytosis of plasma membrane receptors and protein trafficking through these compartments. All members of this protein family contain a phosphoinositide binding domain (PX domain). A highly similar protein in mouse is responsible for the specific recruitment of an isoform of serotonin 5-hydroxytryptamine 4 receptor into early endosomes, suggesting the analogous role for the human protein. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -5 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.56).
BP6
Variant 1-151692482-T-C is Benign according to our data. Variant chr1-151692482-T-C is described in ClinVar as [Likely_benign]. Clinvar id is 531728.Status of the report is criteria_provided_single_submitter, 1 stars.
BP7
Synonymous conserved (PhyloP=2.07 with no splicing effect.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD3 genomes
Cov.:
30
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251310 AF XY: 0.00 show subpopulations
GnomAD2 exomes
AF:
AC:
1
AN:
251310
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000141 AC: 2AN: 1421876Hom.: 0 Cov.: 35 AF XY: 0.00 AC XY: 0AN XY: 706776 show subpopulations
GnomAD4 exome
AF:
AC:
2
AN:
1421876
Hom.:
Cov.:
35
AF XY:
AC XY:
0
AN XY:
706776
show subpopulations
African (AFR)
AF:
AC:
0
AN:
32084
American (AMR)
AF:
AC:
1
AN:
43230
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
24616
East Asian (EAS)
AF:
AC:
0
AN:
36488
South Asian (SAS)
AF:
AC:
0
AN:
85698
European-Finnish (FIN)
AF:
AC:
0
AN:
50868
Middle Eastern (MID)
AF:
AC:
0
AN:
5414
European-Non Finnish (NFE)
AF:
AC:
1
AN:
1085954
Other (OTH)
AF:
AC:
0
AN:
57524
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.550
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome Cov.: 30
GnomAD4 genome
Cov.:
30
ClinVar
Significance: Likely benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Severe myoclonic epilepsy in infancy Benign:1
Mar 06, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.